Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**X-ray repair cross complementing 6 pseudogene 4 (XRCC6P4)** is a pseudogene, not a functional protein-coding gene or traditional drug/therapeutic target. There is no evidence to suggest it expresses a biologically active protein, functions as a receptor, enzyme, transporter, or transcription factor, nor is it implicated directly in human disease mechanisms or therapeutic intervention. XRCC6P4 is annotated in genomic databases as a member of the XRCC (X-ray repair cross complementing) pseudogene family, named in reference to homology with genes involved in DNA repair such as XRCC6 (Ku70), but by definition, pseudogenes like XRCC6P4 lack known, physiologically relevant protein products or pharmacologically actionable roles[1]. **Note:** If you are interested in DNA repair or cancer therapy targets, it is possible you meant XRCC6 (Ku70) or XRCC4, both of which are real DNA repair proteins with well-defined cellular roles and some disease associations, unlike XRCC6P4[2][4][7]. **Summary:** XRCC6P4 is a pseudogene and not a validated molecular or therapeutic target[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on X-ray repair cross complementing 6 pseudogene 4 (XRCC6P4).